These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 19029512

  • 1. Patient page. Progressive supranuclear palsy.
    Karceski S.
    Neurology; 2008 Nov 25; 71(22):e70-2. PubMed ID: 19029512
    [No Abstract] [Full Text] [Related]

  • 2. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
    Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, Premi E, Bonuccelli U, Grassi M, Perani D, Calabresi P, Di Luca M, Padovani A.
    Neurology; 2008 Nov 25; 71(22):1796-803. PubMed ID: 18971445
    [Abstract] [Full Text] [Related]

  • 3. CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias.
    Ballard CG, Jones EL.
    Neurology; 2010 Nov 16; 75(20):1760-1. PubMed ID: 20962288
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Progressive supranuclear palsy finally has a clinically measureable τ abnormality.
    Halliday G.
    J Neurol Neurosurg Psychiatry; 2015 Mar 16; 86(3):241. PubMed ID: 25053767
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tau and saitohin gene expression pattern in progressive supranuclear palsy.
    Ezquerra M, Gaig C, Ascaso C, Muñoz E, Tolosa E.
    Brain Res; 2007 May 11; 1145():168-76. PubMed ID: 17320831
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene.
    Rossi G, Gasparoli E, Pasquali C, Di Fede G, Testa D, Albanese A, Bracco F, Tagliavini F.
    Ann Neurol; 2004 Mar 11; 55(3):448. PubMed ID: 14991829
    [No Abstract] [Full Text] [Related]

  • 14. Differential involvement and heterogeneous phosphorylation of tau isoforms in progressive supranuclear palsy.
    Gibb GM, de Silva R, Revesz T, Lees AJ, Anderton BH, Hanger DP.
    Brain Res Mol Brain Res; 2004 Feb 05; 121(1-2):95-101. PubMed ID: 14969740
    [Abstract] [Full Text] [Related]

  • 15. Hypertension and progressive supranuclear palsy: is everything so clear?
    Sibon I, Macia F, Vital A, Delacourte A, Tison F.
    Mov Disord; 2004 Oct 05; 19(10):1259-61. PubMed ID: 15390036
    [No Abstract] [Full Text] [Related]

  • 16. Neuropathology in the S305S tau gene mutation.
    Halliday GM, Song YJ, Creasey H, Morris JG, Brooks WS, Kril JJ.
    Brain; 2006 Mar 05; 129(Pt 3):E40. PubMed ID: 16477083
    [No Abstract] [Full Text] [Related]

  • 17. Progressive supranuclear palsy.
    Warren NM, Burn DJ.
    Pract Neurol; 2007 Feb 05; 7(1):16-23. PubMed ID: 17430861
    [No Abstract] [Full Text] [Related]

  • 18. The relationship between histopathological features of progressive supranuclear palsy and disease duration.
    Josephs KA, Mandrekar JN, Dickson DW.
    Parkinsonism Relat Disord; 2006 Mar 05; 12(2):109-12. PubMed ID: 16337422
    [Abstract] [Full Text] [Related]

  • 19. Neuropathological diagnosis of progressive supranuclear palsy and related disorders.
    Ikeda K, Akiyama H.
    J Neuropathol Exp Neurol; 1996 Dec 05; 55(12):1278-9. PubMed ID: 8957452
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.